omega-3-carboxylic acids 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	5126	329042-31-1

Description:

Molecule	Description
Synonyms: omega-3-carboxylic acids omega-3 carboxylic acid epanova long chain omega-3 and omega-6 fatty acids	Fish oil-derived free fatty acids including multiple omega-3 fatty acids, eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] being the most abundant. The mechanism of action of omega-3-carboxylic acids is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-carboxylic acids may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

omega-3-carboxylic acids
omega-3 carboxylic acid
epanova
long chain omega-3 and omega-6 fatty acids

Fish oil-derived free fatty acids including multiple omega-3 fatty acids, eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA] being the most abundant. The mechanism of action of omega-3-carboxylic acids is not completely understood. Potential mechanisms of action include inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increased mitochondrial and peroxisomal beta-oxidation in the liver, decreased lipogenesis in the liver, and increased plasma lipoprotein lipase activity. Omega-3-carboxylic acids may reduce the synthesis of triglycerides in the liver because EPA and DHA are poor substrates for the enzymes responsible for TG synthesis, and EPA and DHA inhibit esterification of other fatty acids.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
May 5, 2014	FDA	ASTRAZENECA PHARMS

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA CS	M0023885	Fatty Acids, Omega-3
FDA EPC	N0000175583	Omega-3 Fatty Acid

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Hypertriglyceridemia	indication	302870006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	EPANOVA	ASTRAZENECA	N205060	May 5, 2014	DISCN	CAPSULE	ORAL	8383678	Feb. 7, 2025	TREATMENT OF HYPERTRIGLYCERIDEMIA
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	EPANOVA	ASTRAZENECA	N205060	May 5, 2014	DISCN	CAPSULE	ORAL	9012501	Feb. 7, 2025	TREATMENT OF HYPERTRIGLYCERIDEMIA
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	EPANOVA	ASTRAZENECA	N205060	May 5, 2014	DISCN	CAPSULE	ORAL	9132112	Feb. 7, 2025	TREATMENT OF HYPERTRIGLYCERIDEMIA
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	EPANOVA	ASTRAZENECA	N205060	May 5, 2014	DISCN	CAPSULE	ORAL	10117844	Jan. 4, 2033	TREATMENT OF SEVERE HYPERTRIGLYCERIDEMIA (500 MG/DL) IN ADULT PATIENTS AS AN ADJUNCT TO DIET
1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	EPANOVA	ASTRAZENECA	N205060	May 5, 2014	DISCN	CAPSULE	ORAL	9050308	Jan. 4, 2033	TREATMENT OF HYPERTRIGLYCERIDEMIA

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

ID	Source
CHEMBL3137327	ChEMBL_ID
C000708078	MESH_SUPPLEMENTAL_RECORD_UI
DB09568	DRUGBANK_ID
1652071	RXNORM
234233	MMSL
015520	NDDF
C3832882	UMLSCUI
76322221	PUBCHEM_CID
F85N2YHE4E	UNII

Pharmaceutical products:

None